	US 11,896,675 B2
	Site-specific antibody conjugation and antibody-drug conjugate as specific embodiment thereof
Sang Jeon Chung, Gyeonggi-do (KR); Ju Hwan Kim, Gyeonggi-do (KR); Young Geun Lee, Gyeonggi-do (KR); Tae Jin Lee, Gyeonggi-do (KR); and Jin Woo Seo, Gyeonggi-do (KR)
Assigned to AbTis Co., Ltd., Gyeonggi-do (KR)
Filed by AbTis Co., Ltd., Gyeonggi-do (KR)
Filed on Jan. 16, 2023, as Appl. No. 18/154,998.
Application 18/154,998 is a continuation of application No. 16/980,503, filed on Sep. 14, 2020.
Claims priority of provisional application 62/815,557, filed on Mar. 8, 2019.
Prior Publication US 2023/0248842 A1, Aug. 10, 2023
Int. Cl. A61P 35/00 (2006.01); C07D 207/46 (2006.01); C07K 16/32 (2006.01); A61K 47/68 (2017.01)

CPC A61K 47/6803 (2017.08) [A61K 47/6855 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); C07D 207/46 (2013.01); C07K 16/32 (2013.01)]

13 Claims

1. A modified antibody or its fragment comprising bio-orthogonal click chemistry functional group,

wherein the modified antibody comprises one or more modified heavy chain,

wherein each of the modified heavy chain comprises a modified lysine residue at 248 position of heavy chain amino acid sequence, wherein the 248 position is determined by an EU numbering system, and

wherein the modified lysine residue comprises a bio-orthogonal click chemistry functional group at terminal end, and

wherein the modified lysine residue does not comprise a terminal bio-reactive functional group selected from terminal hydroxy group, terminal carboxyl group, terminal thiol group, terminal amino group, and terminal aldehyde group.